Actinium Pharmaceuticals (ATNM) AI Stock Analysis

• Market Cap: $36.19M
• Dividend Yield: N/A
• Average Volume (3M): 208.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: 11.11%
• EPS Growth: 20.65%
• Country: US
• Employees: 31
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 31,195,890
• 10 Day Avg. Volume: 380,172
• 30 Day Avg. Volume: 208,296
• PEG Ratio: 0.03
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.15
• Enterprise Value/Market Cap: -0.44
• Enterprise Value/Revenue: -178.45
• Enterprise Value/Gross Profit: 22.03
• Enterprise Value/Ebitda: 0.48
• 1Y Price Target: $6.00
• Price Target Upside: 417.24% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-13.79% Downside)

The score is primarily weighed down by weak financial performance—very low revenue, large ongoing losses, and sustained cash burn—partly offset by low leverage. Technicals are neutral-to-weak with the stock trading below key moving averages and only modest momentum. Valuation offers limited support given negative earnings and no dividend.

Positive Factors

Innovative Product Pipeline

The ARC platform represents a significant competitive advantage, potentially offering targeted cancer therapies that spare healthy tissue, which could lead to successful commercialization and partnerships.

Partnership Revenue Model

Actinium's strategy of partnering with larger firms for drug development and commercialization provides a pathway to revenue through upfront and milestone payments, reducing the financial burden of independent development.

Low Debt Levels

A low reliance on debt enhances financial stability and flexibility, allowing the company to focus on R&D and strategic partnerships without the pressure of high interest obligations.

Negative Factors

Negative Revenue Growth

Consistent revenue decline indicates challenges in product commercialization and market penetration, potentially limiting future growth and financial sustainability.

Negative Cash Flow

Persistent negative cash flow from operations suggests that the company is not generating sufficient internal funds, increasing reliance on external financing and posing risks to long-term viability.

Substantial Net Losses

Ongoing net losses highlight operational inefficiencies and high costs relative to revenue, which could hinder investment in R&D and delay the path to profitability.

Actinium Pharmaceuticals Business Overview & Revenue Model

Company Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

How the Company Makes Money

Actinium Pharmaceuticals generates revenue through a combination of partnerships, licensing agreements, and potentially, future sales of its developed therapies. The company's revenue model primarily involves collaborations with larger pharmaceutical companies to co-develop and commercialize its proprietary therapies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its drug candidates. Actinium's focus on advancing its pipeline through clinical trials also positions it to earn revenue from the eventual approval and sale of its therapeutic products. Additionally, the company may engage in research and development agreements with academic and research institutions to further its scientific initiatives.

Actinium Pharmaceuticals Financial Statement Overview

Summary

Financials reflect a development-stage biotech profile: minimal TTM revenue (~$0.09M), deeply negative profitability (TTM net loss ~-$34.6M), and significant cash burn (TTM operating cash flow/free cash flow ~-$25.0M). The main offset is relatively low leverage (debt-to-equity ~0.08), though equity has eroded materially over time, increasing financing/dilution risk.

Income Statement

The income statement remains very weak, reflecting a development-stage profile. TTM (Trailing-Twelve-Months) revenue is minimal ($0.09M) and profitability is deeply negative (TTM net loss of ~$34.6M), with consistently negative operating results across the annual periods provided. While losses narrowed from 2023 to 2024 and further into TTM, margins remain heavily negative and the revenue base is too small to meaningfully absorb operating costs—leaving the earnings outlook highly dependent on future commercialization or partnering success.

Balance Sheet

The balance sheet is a relative strength due to low leverage. TTM debt is ~$1.1M against ~$13.8M of equity (debt-to-equity ~0.08), which reduces financial risk and provides flexibility compared with many loss-making peers. The key weakness is the sharp erosion of equity over time (from ~$73.5M in 2021 to ~$13.8M TTM) driven by persistent losses, which increases dilution/financing risk if cash needs remain elevated.

Cash Flow

Cash flow quality is pressured by sustained cash burn. TTM operating cash flow and free cash flow are both about -$25.0M, and free cash flow declined versus the prior period (negative growth). A positive is that cash burn has moderated versus 2023 and 2024, but the business is still consuming significant cash with no meaningful revenue support, implying ongoing reliance on external funding until profitability or durable revenue ramps.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	90.00K	0.00	81.00K	1.03M	1.14M	0.00
Gross Profit	-729.00K	-811.00K	81.00K	1.03M	620.00K	-447.00K
EBITDA	-33.78M	-37.43M	-51.13M	-33.41M	-24.25M	-21.77M
Net Income	-34.60M	-38.24M	-48.82M	-33.02M	-24.77M	-22.21M
Balance Sheet
Total Assets	56.15M	76.90M	81.44M	114.19M	80.39M	66.40M
Cash, Cash Equivalents and Short-Term Investments	53.39M	72.90M	76.68M	108.91M	77.83M	63.61M
Total Debt	1.14M	1.57M	2.11M	2.58M	310.00K	738.00K
Total Liabilities	42.37M	44.14M	45.07M	47.71M	6.84M	5.08M
Stockholders Equity	13.78M	32.76M	36.38M	66.48M	73.55M	61.32M
Cash Flow
Free Cash Flow	-25.04M	-33.08M	-47.49M	8.28M	-21.00M	-21.87M
Operating Cash Flow	-25.04M	-33.07M	-47.34M	8.64M	-20.87M	-21.62M
Investing Cash Flow	0.00	-11.00K	-153.00K	-366.00K	-133.00K	-253.00K
Financing Cash Flow	-217.00K	29.32M	14.87M	23.11M	35.22M	76.18M

Actinium Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.41, and below the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 33.37 is Neutral, neither overbought nor oversold. The STOCH value of 7.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATNM.

Actinium Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GANX	46 Neutral	$69.23M	-2.78	-261.72%	―	―	42.29%
ATNM	45 Neutral	$36.19M	-1.10	-133.09%	―	11.11%	20.65%
UNCY	44 Neutral	$128.30M	-1.98	-102.47%	―	―	66.05%
IFRX	43 Neutral	$59.22M	-0.93	―	―	―	―

Actinium Pharmaceuticals Corporate Events

Actinium Pharmaceuticals Holds Annual Stockholders Meeting

On November 26, 2025, Actinium Pharmaceuticals held its annual meeting of stockholders, where Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors for a term expiring in 2028. The meeting also saw the ratification of CBIZ as the independent public accounting firm for 2025 and approval of executive compensation-related proposals, reflecting continued shareholder support for the company’s governance and strategic direction.

The most recent analyst rating on (ATNM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Actinium Pharmaceuticals stock, see the ATNM Stock Forecast page.